Treatment of Impaired Glucose Tolerance in Pregnancy (TIP)

This study has been completed.
Uppsala-Örebro Regional Research Council
Information provided by (Responsible Party):
Helena Fadl, University Hospital Orebro Identifier:
First received: February 1, 2008
Last updated: May 10, 2016
Last verified: May 2016
The purpose of this study is to evaluate if treatment (insulin or diet) of pregnant women with impaired glucose tolerance (75-g OGTT with a fasting P-gluc <7.0 mmol/l and 2 h P-gluc >10.0 and <12.2 mmol/l) close to normoglycemia reduces children´s birth weight and neonatal morbidity. There will be a focus on treatment according to specific goals and separate follow-up regimes for the children and women post partum.

Condition Intervention
Impaired Glucose Tolerance
Fetal Macrosomia
Drug: Insulin aspart and Insulin human (isophane)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Randomized Controlled, Multicenter Study Evaluating Treatment of Glucose Intolerance in Pregnancy

Resource links provided by NLM:

Further study details as provided by University Hospital Orebro:

Primary Outcome Measures:
  • Perinatal morbidity and intrauterine growth [ Time Frame: 1 year post partum ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Children´s future health [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 72
Study Start Date: February 2008
Study Completion Date: December 2013
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: B2
IGT randomized to treatment
Drug: Insulin aspart and Insulin human (isophane)
Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
Other Names:
  • NovoRapid FlexPen, A10AB05
  • Insulatard FlexPen, A10AC01
No Intervention: B1
IGT randomized to "no treatment"


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women with 75g OGTT result : fasting capillary plasma <=7.0 mmol/l and/or 2 h value >= 12.2 mmol/l

Exclusion Criteria:

  • Multiple pregnancy
  • Pregestational Diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00625781

University Hospital Örebro
Örebro, Sweden, 70185
Sponsors and Collaborators
University Hospital Orebro
Uppsala-Örebro Regional Research Council
Study Chair: Ulf Hanson, Consultant Uppsala Academic Hospital , Sweden
Principal Investigator: Ingrid Östlund, MD University Hospital Orebro
  More Information

Responsible Party: Helena Fadl, MD, PhD, University Hospital Orebro Identifier: NCT00625781     History of Changes
Other Study ID Numbers: 061018-237  TIP protocol Medscinet 
Study First Received: February 1, 2008
Last Updated: May 10, 2016
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by University Hospital Orebro:
Gestational diabetes mellitus
Impaired glucose Tolerance
Fetal macrosomia
Perinatal morbidity

Additional relevant MeSH terms:
Fetal Macrosomia
Glucose Intolerance
Birth Weight
Body Weight
Diabetes Complications
Diabetes Mellitus
Diabetes, Gestational
Endocrine System Diseases
Fetal Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Pregnancy Complications
Pregnancy in Diabetics
Signs and Symptoms
Insulin Aspart
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on May 24, 2016